Arginine deiminase (ADI) is an enzyme (EC 3.5.3.6) that catalyzes the hydrolytic deimination of L‑arginine to L‑citrulline and ammonia. The reaction can be expressed as:
$$ \text{L‑arginine} + \text{H}_2\text{O} ;\longrightarrow; \text{L‑citrulline} + \text{NH}_3 $$
The enzyme belongs to the family of hydrolases acting on carbon‑nitrogen (C‑N) bonds other than peptide bonds, specifically amidines.
Biochemical Characteristics
| Property | Details |
|---|---|
| Systematic name | L‑arginine amidinohydrolase |
| Common names | Arginine deiminase, ADI, arginine dihydrolase |
| Molecular weight | Typically 40–50 kDa, varying among species |
| Cofactors | No known metal or prosthetic group requirement; activity is dependent on pH and temperature |
| Optimal pH | Generally between 6.0 and 7.5 |
| Optimal temperature | 30–40 °C for mesophilic organisms; thermophilic variants show higher optima |
Biological Role
Arginine deiminase is a key component of the arginine deiminase (ADI) pathway, also referred to as the arginine dihydrolase system. This metabolic route enables certain microorganisms to:
- Generate ATP – The conversion of arginine to citrulline, followed by downstream enzymes (ornithine transcarbamylase and carbamate kinase), yields ATP via substrate‑level phosphorylation.
- Regulate intracellular pH – Production of ammonia raises the pH, helping microbes survive acidic environments.
- Contribute to virulence – In pathogenic bacteria such as Streptococcus pyogenes, Pseudomonas aeruginosa, and Mycoplasma spp., the ADI pathway supports colonization and immune evasion.
The pathway proceeds as follows:
- Arginine deiminase converts L‑arginine → L‑citrulline + NH₃.
- Citrulline diacetyl‑ or carbamoyl‑phosphate synthetase (often termed ornithine transcarbamylase) converts citrulline → carbamoyl‑phosphate.
- Carbamate kinase converts carbamoyl‑phosphate → ATP + CO₂ + NH₃.
Structural Information
Crystal structures of arginine deiminases from several bacterial species (e.g., Pseudomonas aeruginosa, Streptococcus spp.) have been resolved to resolutions ranging from 1.8 Å to 2.5 Å. Common structural features include:
- A TIM‑barrel (α/β)8 fold forming the catalytic core.
- An active site located at the barrel’s C‑terminal end, containing residues essential for substrate binding (e.g., Asp, His, and Cys).
- No requirement for metal ions; catalysis involves nucleophilic attack by a conserved cysteine residue on the guanidinium group of arginine.
Distribution
Arginine deiminase is found in a wide range of prokaryotes, including:
- Gram‑positive bacteria: Streptococcus spp., Enterococcus spp., Lactobacillus spp.
- Gram‑negative bacteria: Pseudomonas aeruginosa, Helicobacter pylori (limited).
- Archaea: Certain halophilic archaea possess ADI homologs.
The enzyme is absent from mammalian genomes, making it a target for antimicrobial strategies.
Applications
| Field | Usage |
|---|---|
| Medical diagnostics | ADI activity is employed as a phenotypic marker for bacterial identification in clinical microbiology. |
| Therapeutics | Recombinant arginine deiminase is investigated as an anti‑cancer agent, exploiting the dependence of some tumor cells on extracellular arginine (arginine‑deprivation therapy). |
| Food industry | ADI-producing starter cultures are used to control pH in fermented foods, enhancing safety and flavor. |
| Biotechnology | Enzyme immobilization for biosensors detecting arginine or monitoring metabolic fluxes. |
Genetics
The arcA gene commonly encodes arginine deiminase. In many bacteria, it is part of an operon (arcABC) alongside arcB (ornithine transcarbamylase) and arcC (carbamate kinase). Regulation of the operon is often responsive to arginine availability, carbon source, and environmental pH, mediated by transcriptional regulators such as ArcR or ArgR.
References
- Smith, J. A., & Jones, M. L. (2020). Structure and mechanism of bacterial arginine deiminase. Journal of Molecular Biology, 432(15), 3785–3798.
- Patel, R. et al. (2019). Arginine deiminase pathway as a target for antimicrobial therapy. Clinical Microbiology Reviews, 32(3), e00082‑18.
- Lee, Y. H. & Park, S. J. (2021). Recombinant arginine deiminase in cancer treatment: progress and challenges. Oncotarget, 12(9), 837‑849.
(All references are illustrative; actual citations should be consulted for detailed study.)